XBiotech Overview

  • Founded
  • 2005

Founded
  • Status
  • Public

  • Employees
  • 94

Employees
  • Stock Symbol
  • XBIT

Stock Symbol
  • Share Price
  • $5.64

  • (As of Friday Closing)

XBiotech General Information

Description

XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 5217 Winnebago Lane
  • Austin, TX 78744
  • United States
+1 (512) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

XBiotech Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.64 $5.63 $5.09 - $18.46 $172M 30.4M 142K -$0.67

XBiotech Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 26,012 99,467 219,498 726,545
Revenue 14,044 18,394 43,997 0
EBITDA (26,590) (23,277) (13,045) 720,250
Net Income (20,241) (17,414) (11,221) 668,629
Total Assets 270,803 275,177 353,744 816,877
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

XBiotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore XBiotech‘s full profile, request access.

Request a free trial

XBiotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and develop
Biotechnology
Austin, TX
94 As of 2022
0000
0000 0000-00-00
00000000 0000

000 00

a. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Epalinges, Switzerland
000 As of 0000
00.000
00000000 00.000

000000

si ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit ess
0000000000000
San Francisco, CA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

XBiotech Competitors (90)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
000000000 00000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
00000 Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
0000 00000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
00000 000000000000 Formerly VC-backed London, United Kingdom 00 00000 000000000 00000
You’re viewing 5 of 90 competitors. Get the full list »

XBiotech Patents

XBiotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210017257-A1 Compositions and methods for treating and preventing staphylococcus aureus infections Pending 30-Jun-2017 00000000000
AU-2015271749-B2 Compositions and methods for treating and preventing staphylococcus aureus infections Active 03-Jun-2014 00000000000 0
CA-2950840-A1 Compositions and methods for treating and preventing staphylococcus aureus infections Pending 03-Jun-2014 0000000000
AU-2018200886-B2 Compositions and methods for treating and preventing staphylococcus aureus infections Active 03-Jun-2014 00000000000 0
AU-2018200886-A1 Compositions and methods for treating and preventing staphylococcus aureus infections Granted 03-Jun-2014 A61K39/395
To view XBiotech’s complete patent history, request access »

XBiotech Executive Team (6)

Name Title Board Seat Contact Info
John Simard Chief Executive Officer & Chairman
Queena Han Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Sushma Shivaswamy Chief Scientific Officer
Robert Lindsey JD Senior Vice President, Corporate Development & General Counsel
Benjamin Guzman Senior Vice President of Corporate Strategy, Financial & Management
You’re viewing 5 of 6 executive team members. Get the full list »

XBiotech Board Members (1)

Name Representing Role Since
0000 000000 XBiotech Chief Executive Officer & Chairman 000 0000
To view XBiotech’s complete board members history, request access »

XBiotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial